CLRB - Cellectar Biosciences to Present at the Targeted Radiopharmaceuticals Summit Europe | Benzinga
FLORHAM PARK, N.J., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that Jarrod Longcor, Cellectar's chief operating officer (COO), will deliver a presentation and co-chair the 5th Annual Targeted Radiopharmaceuticals Summit Europe, being held December 5-7, 2023 in Berlin, Germany.
Cellectar at the Targeted Radiopharmaceuticals Summit Europe
Presentation Title: Advancing Universal Targeted Radiotherapies: Unleashing the Potential of Alpha & Beta Particles for Solid & Hematologic Malignancies
Date/Time: Thursday, December 7, 2023 at 11:30 a.m. CET
Session: Delving into Isotopes to Maximise the Efficacy of Your TRP
Location: Berlin Marriott Hotel
"This conference unites global radiopharmaceutical innovators and leaders to complete a deep dive into the successes, new scientific breakthroughs, and complexities of radiopharmaceuticals. We look forward to discussing the versatility of Cellectar's proprietary PLE delivery platform, which targets unique changes in the cancerous cell membranes, presenting an opportunity to be a universal targeting agent," said Jarrod Longcor, Cellectar's COO. "Additionally, I am honored to be chosen to co-chair the Radiopharmaceuticals Summit Europe Conference in support ...